Send to

Choose Destination
PLoS Curr. 2011 Nov 13;3:RRN1283. doi: 10.1371/currents.RRN1283.

Use of Tetrabenazine in Huntington Disease Patients on Antidepressants or with Advanced Disease: Results from the TETRA-HD Study.

Author information

Neurologist, Johns Hopkins University; Department of Neurology, University of Rochester, Rochester, NY, USA; University of Rochester Medical Center, Rochester NY; Movement Disorders Fellow, Johns Hopkins University; Partner, KM Pharmaceutical Consulting; Associate Professor of Neurology, University of Rochester School of Medicine and Dentistry; Professor of Neurology, Pharmacology & Human Science. Director, Program for Regulatory Science & Medicine (PRSM) and Doctor.


The safety and effectiveness of tetrabenazine in different sub-populations of Huntington disease (HD) is not known. In this study, we evaluated the safety of tetrabenazine in individuals on an antidepressant and its effectiveness in advanced HD. Tetrabenazine was not associated with an increased incidence of depressed mood among those taking antidepressants and was effective at reducing chorea in those with advanced HD.

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center